- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA's Global Strategy Against Counterfeit Medications
Earlier this month, the FDA took steps to prevent the online sale of counterfeit and illegal medicinal products, which can be a significant health risk to the population.
Earlier this month, the FDA took steps to prevent the online sale of counterfeit and illegal medicinal products, which can be a significant health risk to the population.
Operation Pangea VIII, which spanned 115 countries, resulted in more than 2400 websites being taken offline and the seizure of $81 million worth of potential dangerous illegal medicines and medical devices worldwide. The current effort was a part of FDA's Global Strategic Framework for counterfeit and substandard medical products that strives to protect consumers by reducing their exposure to counterfeit and substandard medical products.
Read more about the FDA's effort on FDAVoice.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
March 10th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
